RxDoctor Payments Data

William Downey, MD

Cardiovascular Disease · Charlotte, NCNPI 1063475226

Payments from drug & device makers

$5,022in general payments, 2019–2025

Across 39 payments — averaging $128.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Boston Scientific$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$376
  • Edwards Lifesciences$178
  • Abiomed$36
  • Novartis$36
  • plus $49 from 2 others

What the payments were for

  • Travel & lodging$3,65073%
  • Food & beverage$1,37227%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic17$3,010
Boston Scientific9$1,338
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)4$376
Edwards Lifesciences4$178
Abiomed1$36
Novartis2$36
Atricure, Inc.1$26
Merge Healthcare Incorporated1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,022 in reported general payments places this provider in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$82,770
Medicare patients
400
Services billed
1,088

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$174,821
JardianceEmpagliflozin39$57,592
EntrestoSacubitril/Valsartan33$46,460
Repatha SureclickEvolocumab32$30,234
Ezetimibe160$4,169
Metoprolol Succinate214$3,195
Atorvastatin Calcium292$2,637
Nifedipine ErNifedipine111$1,939
Amlodipine Besylate230$1,579
Diltiazem 24hr Er (Cd)Diltiazem Hcl49$1,344
Losartan Potassium157$1,270
Valsartan28$1,138
Rosuvastatin Calcium81$1,036
ClopidogrelClopidogrel Bisulfate64$955
Hydralazine Hcl42$773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36$46,46033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →